Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to sign a written consent form agreeing to take part in the study
- You are willing and able to attend scheduled appointments and follow the study procedures
- You are a male or female between 18 and 85 years old
- You have been diagnosed with a type of heart condition called obstructive hypertrophic cardiomyopathy, meaning part of your heart wall is thickened in a way that cannot be explained by other conditions like high blood pressure or valve problems (confirm with trial site for exact measurements)
- You have already been prescribed a medication called mavacamten by your doctor, in line with its approved prescribing guidelines
- You are able and intend to take mavacamten as prescribed by your doctor throughout the study
- If you are a woman who could become pregnant, you must have a negative pregnancy test at the start of the study and at the 12-month visit
Who may not be able to join:
- You are currently pregnant or breastfeeding
- You have a known allergy or sensitivity to mavacamten or a substance called regadenoson
- You have previously been treated with mavacamten or a similar drug called aficamten
- You weigh more than the weight limit allowed for the imaging equipment used in the study (confirm with trial site)
- You have reduced heart pumping function or a lung condition that could affect the quality of the scan images used in this study (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in myocardial perfusion reserve after 12 months of mavacamten treatment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.